BEIJING
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that 10 studies from InnoCare’s oncology pipeline were selected for presentation at the 65th American Society of Hematology (ASH) Annual Meeting on December 9-12, 2023 in San Diego, California, United States.
|
Title |
Report Information |
|
Oral Presentation |
|
|
A Prospective Multicenter Phase II Study of Orelabrutinib-Lenalidomide-Rituximab (OLR) in Patients with Untreated Mantle Cell Lymphoma (MCL) in China (POLARIS Study): Preliminary Analysis on Efficacy, Safety, Mutation Spectrum and Impact of Mutation Profiling on Treatment Responses |
Abstract Number: 736 Session Name: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II Presentation Time: 11:15 AM, Dec. 11, 2023 (Monday, EST)
|
|
Poster Presentation |
|
|
Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study) |
Abstract Number: 4642 Session Name: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III Presentation Time: 6:00 PM – 8:00 PM, Dec. 11, 2023 (Monday, EST) First Presenter: Huayuan Zhu |
|
Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Waldenström’s Macroglobulinemia in a Single-Arm, Multicenter, Open-Label, Phase 2 Study: Long Term Follow-up Results |
Abstract Number: 3039 Session Name: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II Presentation Time: 6:00 PM – 8:00 PM, Dec. 10, 2023 (Sunday, EST) First Presenter: Xinxin Cao |
|
Online Publication |
|
|
Preliminary Safety, Pharmacological, and Efficacy Data from Patients with Relapsed or Refractory B-cell Malignancies Treated with the ICP-248, a Next Generation BCL2 Inhibitor |
Abstract Number: 6149 First Presenter/Corresponding Presenter: Shuhua Yi |
|
Effectiveness and Safety of Orelabrutinib Combined with Rituximab As First-Line Treatment in Marginal Zone Lymphoma |
Abstract Number: 6146 First Presenter: Jiadai Xu Corresponding Presenter: Peng Liu |
|
Orelabrutinib plus R-CHOP Regimen in Treatment-Naïve Patients with TP53-Mutated Diffuse Large B-Cell Lymphoma (DLBCL) |
Abstract Number: 6289 First Presenter/Corresponding Presenter: Yi Xiao |
|
Efficacy and Safety of Orelabrutinib – Containing TORM Regime as First-Line Therapy in Primary Central Nervous System Lymphoma (PCNSL): A Retrospective Analysis |
Abstract Number: 6322 First Presenter: Shaojie Wu Corresponding Presenter: Yuhua Li |
|
Phase 1 Trial of Orelabrutinib in Combination with Rituximab, Methotrexate, and Dexamethasone in Patients with Newly Diagnosed Primary CNS Lymphoma Implementing Bayesian Design for Dose-Seeking |
Abstract Number: 6225 First Presenter: Yan Yuan Corresponding Presenter: Tong Chen |
|
Effectiveness and Safety of Orelabrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Retrospective, Real-World Study in China |
Abstract Number: 6552 First Presenter: Kaiyang Ding Corresponding Presenter: Chunyan Ji |
|
Pomalidomide, Rituximab, Orelabrutinib, and Minichop-like (PRO-miniCHOP) in Elderly Patients with Newly Diagnosed Diffuse Large-B Cell Lymphoma: Preliminary Results from a Phase II Study |
Abstract Number: 6238 First Presenter: Nana Ping Corresponding Presenter: Zhengming Jin |
About Orelabrutinib
Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases.
On Dec. 25, 2020, orelabrutinib received approval from the China National Medical Products Administration (NMPA) in two indications: the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL). At the end of 2021, orelabrutinib was included into the National Reimbursement Drug list, allowing it to benefit more lymphoma patients. On Nov. 22, 2022, orelabrutinib was approved for the treatment of R/R MCL in Singapore. On April 20, 2023, orelabrutinib was approved for the treatment r/r MZL in China.
In addition to the approved indications, multi-center, multi-indication clinical trials are underway in the US and China with orelabrutinib as monotherapy or in combination therapies, such as for the first line treatment of MCD subtype of diffuse large B-cell lymphoma (DLBCL).
Orelabrutinib was granted Breakthrough Therapy Designation for the treatment of r/r MCL by U.S. Food and Drug Administration (FDA). Patient enrollment of the phase II registrational trial for R/R MCL was completed in the U.S. The Company expects to submit the NDA to the U.S. Food and Drug Administration (US FDA) in the middle of 2024.
In addition, orelabrutinib is being advanced in other autoimmune trials, worldwide, including: a phase III registrational trial for the treatment of primary immune thrombocytopenia purpura (ITP) ongoing in China, a global phase II study for the treatment of Multiple Sclerosis (MS), a phase II study for the treatment of SLE in China that has achieved proof of concept (PoC), and a phase II study for the treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) ongoing in China.
About InnoCare
InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and United States.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231114350129/en/
CONTACT
Media
Chunhua Lu
86-10-66609879
chunhua.lu@innocarepharma.com
Investor Relations
86-10-66609999
ir@innocarepharma.com
